Results 81 to 90 of about 12,783,707 (261)
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Comparisons of serum CTLA-4 levels between treated and Untreated SCLC and NSCLC Patients
مجلة كلية الطبBackground: Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer and major causes of cancer-related death worldwide. Objectives: To compare serum cytotoxic T-lymphocyte-associated antigen 4 levels between treated
Zinah Al-Hayali, Rasha Al-Humairi
doaj +1 more source
Tumor Biology, 2017 Lung cancer, especially the non-small-cell lung cancer, is a highly aggressive vascular cancer with excessively activated signaling pathways. Tumor-associated calcium signal transducer 2, also known as trop2, was identified to be correlated with tumor ...
Xiaobin Guo +5 more
doaj +1 more source
Molecular Oncology, EarlyView.Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park +6 more
wiley +1 more source
Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology
Molecular Oncology, EarlyView.This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic +15 more
wiley +1 more source
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
, 2021 Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed.
core +1 more source
Asparagine synthetase (ASNS) Drives Tumorigenicity in Small Cell Lung Cancer
BiomedicinesObjectives: Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma characterized by rapid proliferation, early metastasis, and limited therapeutic response.
Minho Jeong +5 more
doaj +1 more source
Molecular Oncology, EarlyView.LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
, 2017 Objective: Previous studies have indicated that EGFR exon 19 deletions in non-small cell lung cancer (NSCLC) are associated with better outcomes to tyrosine kinase inhibitors (TKIs) than the L858R mutation.
Chen, Li-Yang;Molina-Vila, Miguel A.;Ruan, Sheng-Yuan;Su, Kang-Yi;Liao, Wei-Yu;Yu, Kai-Lun;Ho, Chao-Chi;Shih, Jin-Yuan;Yu, Chong-Jen;Yang, James Chih-Hsin;Rosell, Rafael;Yang, Pan-Chyr +1 more
core +1 more source
Afatinib treatment in advanced non-small cell lung cancer
Lung Cancer: Targets and Therapy, 2011 Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj